Endometrial Cancer - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：167頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Endometrial Cancer - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Endometrial Cancer - Pipeline Review, H1 2014’, provides an overview of the Endometrial Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Endometrial Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Endometrial Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Endometrial Cancer - Pipeline Review, H1 2014’, provides an overview of the Endometrial Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Endometrial Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Endometrial Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Endometrial Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Endometrial Cancer - Overview 11
Pipeline Products for Endometrial Cancer - Comparative Analysis 12
Endometrial Cancer - Therapeutics under Development by Companies 13
Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes 16
Endometrial Cancer - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Endometrial Cancer - Products under Development by Companies 21
Endometrial Cancer - Products under Investigation by Universities/Institutes 23
Endometrial Cancer - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
Boehringer Ingelheim GmbH 25
GlaxoSmithKline plc 26
Merck & Co., Inc. 27
Ipsen S.A. 28
Novartis AG 29
Eisai Co., Ltd. 30
ImmunoGen, Inc. 31
Pfizer Inc. 32
Taiho Pharmaceutical Co., Ltd. 33
Exelixis, Inc. 34
AEterna Zentaris Inc. 35
Ariad Pharmaceuticals, Inc. 36
Critical Outcome Technologies Inc. 37
ArQule, Inc. 38
Galena Biopharma, Inc. 39
Scancell Holdings Plc 40
Oryzon Genomics S.A. 41
Acceleron Pharma, Inc. 42
Arno Therapeutics, Inc. 43
Esperance Pharmaceuticals, Inc. 44
Pharmsynthez 45
Igenica, Inc. 46
OncoHoldings, Inc. 47
Endometrial Cancer - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 54
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
zoptarelin doxorubicin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ixabepilone - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
lenvatinib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MK-2206 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PF-05212384 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ridaforolimus - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
dalantercept - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
cabozantinib (s)-malate - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
nintedanib - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
EP-100 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
dovitinib lactate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
buparlisib hydrochloride - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Virexxa - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
GALE-301 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
GSK-2636771 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
GSK-2141795 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
GSK-2256098 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
GSK-2141795 + trametinib - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
IMGN-853 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
ARQ-092 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
onapristone ER - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
COTI-2 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
EP-200 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
ONCO-101 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
TAS-2985 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
SERD 2 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
(ponatinib + ridaforolimus) - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Virexxa - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Monoclonal Antibody For Endometrial Cancer - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Small Molecules for Oncology and Infectious Disease - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Dual Aromatase and Steroid Sulphatase Inhibitors - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
AKR1C-3 Inhibitors - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
fendiline - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Fendiline Derivatives - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
CRC-06 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Modi-1 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
irosustat + Hormonal Therapy - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Endometrial Cancer - Recent Pipeline Updates 121
Endometrial Cancer - Dormant Projects 156
Endometrial Cancer - Discontinued Products 157
Endometrial Cancer - Product Development Milestones 158
Featured News & Press Releases 158
Feb 04, 2014: Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer 158
Feb 03, 2014: Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin at Upcoming International Symposium on GnRH 159
Sep 09, 2013: Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors 159
Aug 21, 2013: Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance 160
Jul 31, 2013: Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin 160
Jun 11, 2013: Critical Outcome Technologies Announces Positive Preclinical Results Of Cancer Drug Candidiate COTI-2 Against p53 Gene Mutations 161
Jun 03, 2013: Galena Biopharma Provides Update On Folate Binding Protein At ASCO 2013 Annual Meeting 162
May 31, 2013: Kevelt To Produce Virexxa For Treatment Of Advanced And Relapsing Endometrial Cancer 163
May 17, 2013: Eisai To Present Clinical Data On Lenvatinib At ASCO Annual Meeting 163
May 15, 2013: Arno Therapeutics To Present Positive New Data On Onapristone In Endometrial And Breast Cancers At ASCO 2013 Annual Meeting 164
Appendix 166
Methodology 166
Coverage 166
Secondary Research 166
Primary Research 166
Expert Panel Validation 166
Contact Us 167
Disclaimer 167
List of Tables
Number of Products under Development for Endometrial Cancer, H1 2014 11
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Comparative Analysis by Unknown Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Development by Companies, H1 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2014 23
Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2014 24
Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 25
Endometrial Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 26
Endometrial Cancer - Pipeline by Merck & Co., Inc., H1 2014 27
Endometrial Cancer - Pipeline by Ipsen S.A., H1 2014 28
Endometrial Cancer - Pipeline by Novartis AG, H1 2014 29
Endometrial Cancer - Pipeline by Eisai Co., Ltd., H1 2014 30
Endometrial Cancer - Pipeline by ImmunoGen, Inc., H1 2014 31
Endometrial Cancer - Pipeline by Pfizer Inc., H1 2014 32
Endometrial Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 33
Endometrial Cancer - Pipeline by Exelixis, Inc., H1 2014 34
Endometrial Cancer - Pipeline by AEterna Zentaris Inc., H1 2014 35
Endometrial Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 36
Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2014 37
Endometrial Cancer - Pipeline by ArQule, Inc., H1 2014 38
Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H1 2014 39
Endometrial Cancer - Pipeline by Scancell Holdings Plc, H1 2014 40
Endometrial Cancer - Pipeline by Oryzon Genomics S.A., H1 2014 41
Endometrial Cancer - Pipeline by Acceleron Pharma, Inc., H1 2014 42
Endometrial Cancer - Pipeline by Arno Therapeutics, Inc., H1 2014 43
Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2014 44
Endometrial Cancer - Pipeline by Pharmsynthez, H1 2014 45
Endometrial Cancer - Pipeline by Igenica, Inc., H1 2014 46
Endometrial Cancer - Pipeline by OncoHoldings, Inc., H1 2014 47
Assessment by Monotherapy Products, H1 2014 48
Assessment by Combination Products, H1 2014 49
Number of Products by Stage and Target, H1 2014 52
Number of Products by Stage and Mechanism of Action, H1 2014 56
Number of Products by Stage and Route of Administration, H1 2014 59
Number of Products by Stage and Molecule Type, H1 2014 61
Endometrial Cancer Therapeutics - Recent Pipeline Updates, H1 2014 121
Endometrial Cancer - Dormant Projects, H1 2014 156
Endometrial Cancer - Discontinued Products, H1 2014 157
List of Figures
Number of Products under Development for Endometrial Cancer, H1 2014 11
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 48
Assessment by Combination Products, H1 2014 49
Number of Products by Top 10 Target, H1 2014 50
Number of Products by Stage and Top 10 Target, H1 2014 51
Number of Products by Top 10 Mechanism of Action, H1 2014 54
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 55
Number of Products by Top 10 Route of Administration, H1 2014 58
Number of Products by Stage and Top 10 Route of Administration, H1 2014 59
Number of Products by Top 10 Molecule Type, H1 2014 60
Number of Products by Stage and Top 10 Molecule Type, H1 2014 61
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Endometrial Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Endometrial Cancer - Overview 11
Pipeline Products for Endometrial Cancer - Comparative Analysis 12
Endometrial Cancer - Therapeutics under Development by Companies 13
Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes 16
Endometrial Cancer - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Endometrial Cancer - Products under Development by Companies 21
Endometrial Cancer - Products under Investigation by Universities/Institutes 23
Endometrial Cancer - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
Boehringer Ingelheim GmbH 25
GlaxoSmithKline plc 26
Merck & Co., Inc. 27
Ipsen S.A. 28
Novartis AG 29
Eisai Co., Ltd. 30
ImmunoGen, Inc. 31
Pfizer Inc. 32
Taiho Pharmaceutical Co., Ltd. 33
Exelixis, Inc. 34
AEterna Zentaris Inc. 35
Ariad Pharmaceuticals, Inc. 36
Critical Outcome Technologies Inc. 37
ArQule, Inc. 38
Galena Biopharma, Inc. 39
Scancell Holdings Plc 40
Oryzon Genomics S.A. 41
Acceleron Pharma, Inc. 42
Arno Therapeutics, Inc. 43
Esperance Pharmaceuticals, Inc. 44
Pharmsynthez 45
Igenica, Inc. 46
OncoHoldings, Inc. 47
Endometrial Cancer - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 54
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
zoptarelin doxorubicin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ixabepilone - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
lenvatinib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MK-2206 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PF-05212384 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ridaforolimus - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
dalantercept - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
cabozantinib (s)-malate - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
nintedanib - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
EP-100 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
dovitinib lactate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
buparlisib hydrochloride - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Virexxa - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
GALE-301 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
GSK-2636771 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
GSK-2141795 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
GSK-2256098 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
GSK-2141795 + trametinib - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
IMGN-853 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
ARQ-092 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
onapristone ER - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
COTI-2 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
EP-200 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
ONCO-101 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
TAS-2985 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
SERD 2 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
(ponatinib + ridaforolimus) - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Virexxa - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Monoclonal Antibody For Endometrial Cancer - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Small Molecules for Oncology and Infectious Disease - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Dual Aromatase and Steroid Sulphatase Inhibitors - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
AKR1C-3 Inhibitors - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
fendiline - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Fendiline Derivatives - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
CRC-06 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Modi-1 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
irosustat + Hormonal Therapy - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Endometrial Cancer - Recent Pipeline Updates 121
Endometrial Cancer - Dormant Projects 156
Endometrial Cancer - Discontinued Products 157
Endometrial Cancer - Product Development Milestones 158
Featured News & Press Releases 158
Feb 04, 2014: Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer 158
Feb 03, 2014: Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin at Upcoming International Symposium on GnRH 159
Sep 09, 2013: Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors 159
Aug 21, 2013: Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance 160
Jul 31, 2013: Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin 160
Jun 11, 2013: Critical Outcome Technologies Announces Positive Preclinical Results Of Cancer Drug Candidiate COTI-2 Against p53 Gene Mutations 161
Jun 03, 2013: Galena Biopharma Provides Update On Folate Binding Protein At ASCO 2013 Annual Meeting 162
May 31, 2013: Kevelt To Produce Virexxa For Treatment Of Advanced And Relapsing Endometrial Cancer 163
May 17, 2013: Eisai To Present Clinical Data On Lenvatinib At ASCO Annual Meeting 163
May 15, 2013: Arno Therapeutics To Present Positive New Data On Onapristone In Endometrial And Breast Cancers At ASCO 2013 Annual Meeting 164
Appendix 166
Methodology 166
Coverage 166
Secondary Research 166
Primary Research 166
Expert Panel Validation 166
Contact Us 167
Disclaimer 167
List of Tables
Number of Products under Development for Endometrial Cancer, H1 2014 11
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Comparative Analysis by Unknown Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Development by Companies, H1 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2014 23
Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2014 24
Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 25
Endometrial Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 26
Endometrial Cancer - Pipeline by Merck & Co., Inc., H1 2014 27
Endometrial Cancer - Pipeline by Ipsen S.A., H1 2014 28
Endometrial Cancer - Pipeline by Novartis AG, H1 2014 29
Endometrial Cancer - Pipeline by Eisai Co., Ltd., H1 2014 30
Endometrial Cancer - Pipeline by ImmunoGen, Inc., H1 2014 31
Endometrial Cancer - Pipeline by Pfizer Inc., H1 2014 32
Endometrial Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 33
Endometrial Cancer - Pipeline by Exelixis, Inc., H1 2014 34
Endometrial Cancer - Pipeline by AEterna Zentaris Inc., H1 2014 35
Endometrial Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 36
Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2014 37
Endometrial Cancer - Pipeline by ArQule, Inc., H1 2014 38
Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H1 2014 39
Endometrial Cancer - Pipeline by Scancell Holdings Plc, H1 2014 40
Endometrial Cancer - Pipeline by Oryzon Genomics S.A., H1 2014 41
Endometrial Cancer - Pipeline by Acceleron Pharma, Inc., H1 2014 42
Endometrial Cancer - Pipeline by Arno Therapeutics, Inc., H1 2014 43
Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2014 44
Endometrial Cancer - Pipeline by Pharmsynthez, H1 2014 45
Endometrial Cancer - Pipeline by Igenica, Inc., H1 2014 46
Endometrial Cancer - Pipeline by OncoHoldings, Inc., H1 2014 47
Assessment by Monotherapy Products, H1 2014 48
Assessment by Combination Products, H1 2014 49
Number of Products by Stage and Target, H1 2014 52
Number of Products by Stage and Mechanism of Action, H1 2014 56
Number of Products by Stage and Route of Administration, H1 2014 59
Number of Products by Stage and Molecule Type, H1 2014 61
Endometrial Cancer Therapeutics - Recent Pipeline Updates, H1 2014 121
Endometrial Cancer - Dormant Projects, H1 2014 156
Endometrial Cancer - Discontinued Products, H1 2014 157
List of Figures
Number of Products under Development for Endometrial Cancer, H1 2014 11
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 48
Assessment by Combination Products, H1 2014 49
Number of Products by Top 10 Target, H1 2014 50
Number of Products by Stage and Top 10 Target, H1 2014 51
Number of Products by Top 10 Mechanism of Action, H1 2014 54
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 55
Number of Products by Top 10 Route of Administration, H1 2014 58
Number of Products by Stage and Top 10 Route of Administration, H1 2014 59
Number of Products by Top 10 Molecule Type, H1 2014 60
Number of Products by Stage and Top 10 Molecule Type, H1 2014 61
